Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc. is listed today as Pliant Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2019 | $100 M | No. 2 | $50 to $250 million | equity | SEC | |
| Jul 2018 | $62 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Pliant Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2020).
SEC Form D · Mar 2020
The industry group it chose in its notices: Biotechnology.
SEC Form D · Mar 2020
That is all the official record says: Pliant Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Pliant Therapeutics, Inc. are on record.
Investors#
10 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Barbara Howes | Person | not stated | not stated | Held Series C preferred stock (Form 3, 2020) | SEC Form 3 |
| Hans Hull | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2020) | SEC Form 3 |
| Keith Lamont Cummings | Person | not stated | not stated | Held Series C preferred stock (Form 3, 2020) | SEC Form 3 |
| Redmile Group, LLC | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Third Rock Ventures GP III, L.P. | Venture capital | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Third Rock Ventures GP IV, L.P. | Venture capital | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Third Rock Ventures III, L.P. | Venture capital | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Third Rock Ventures IV, L.P. | Venture capital | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| TRV GP III, LLC | Other | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Trv Gp Iv, LLC | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 66 investors.
Largest shareholders today
Institutions holding Pliant Therapeutics, Inc. shares, as of Sep 30, 2026.
- Tang Capital Management LLC$7 M9.91%
- ADAR1 Capital Management, LLC$6 M8.89%
- Acadian Asset Management LLC$3 M3.90%
- Vanguard Capital Management LLC$3 M3.89%
- Two Sigma Investments, LP$2 M3.64%
- Renaissance Technologies LLC$2 M3.31%
- Monaco Asset Management SAM$2 M3.24%
- Lynx1 Capital Management LP$2 M2.90%
- Woodline Partners LP$2 M2.63%
- Prosight Management, LP$2 M2.59%
- BML Capital Management, LLC$2 M2.49%
- Peapod Lane Capital LLC$1 M1.96%
- BlackRock, Inc.$1 M1.86%
- Ikarian Capital, LLC$1 M1.61%
- Eversept Partners, LP$1 M1.43%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Barbara Howes | Executive officer | Mar 2020 |
| Bernard Coulie | Executive officer | Mar 2020 |
| Eric Lefebvre | Executive officer | Mar 2020 |
| Johannes Hull | Executive officer | Mar 2020 |
| Keith Cummings | Executive officer | Mar 2020 |
| Bernard Coulie | Director | Mar 2020 |
| Charles Homcy | Director | Mar 2020 |
| Gayle Crowell | Director | Mar 2020 |
| Hoyoung Huh | Director | Mar 2020 |
| John Curnutte | Director | Mar 2020 |
| Kevin Raidy | Director | Mar 2020 |
| Neil Exter | Director | Mar 2020 |
| Smital Shah | Director | Mar 2020 |
| Suzanne Bruhn | Director | Mar 2020 |
About
Company in South San Francisco, United States.
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.